Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sage Therapeutic Com (SAGE)

Sage Therapeutic Com (SAGE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 543,550
  • Shares Outstanding, K 62,621
  • Annual Sales, $ 41,240 K
  • Annual Income, $ -400,670 K
  • EBIT $ -360 M
  • EBITDA $ -366 M
  • 60-Month Beta 0.29
  • Price/Sales 13.21
  • Price/Cash Flow N/A
  • Price/Book 1.47
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -5.80
  • Most Recent Earnings $-0.79 on 07/30/25
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate -0.79
  • Number of Estimates 8
  • High Estimate -0.10
  • Low Estimate -0.96
  • Prior Year -1.53
  • Growth Rate Est. (year over year) +48.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.68 unch
on 07/30/25
9.36 -7.26%
on 07/11/25
-0.44 (-4.82%)
since 06/30/25
3-Month
6.35 +36.69%
on 05/30/25
9.36 -7.26%
on 07/11/25
+1.39 (+19.07%)
since 04/30/25
52-Week
4.62 +87.88%
on 11/20/24
11.44 -24.10%
on 07/31/24
-2.12 (-19.63%)
since 07/30/24

Most Recent Stories

More News
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) (“Supernus”) today announced that it has successfully completed its previously announced acquisition...

SUPN : 46.97 (-0.40%)
SAGE : 8.68 (-0.23%)
Sage Therapeutics Announces Second Quarter 2025 Financial Results

Achieved $23.2 million in ZURZUVAE ® (zuranolone) collaboration revenue in the second quarter of 2025 (50% of the net revenues recorded by Biogen),...

SAGE : 8.68 (-0.23%)
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer

ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) (" Supernus ", and the "Company"), today announced that the required waiting period...

SUPN : 46.97 (-0.40%)
SAGE : 8.68 (-0.23%)
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression

CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive...

SAGE : 8.68 (-0.23%)
BIIB : 179.46 (-0.54%)
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032

CMPS : 6.45 (+2.38%)
CYBN.NE : 8.3000 (+1.97%)
ATAI : 4.44 (-0.22%)
MMED.NE : 14.9000 (+9.48%)
SAGE : 8.68 (-0.23%)
MNMD : 12.65 (-2.69%)
CYBN : 5.93 (+0.34%)
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032

EQNX::TICKER_START (NYSE:CYBN),(NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:SAGE),(NASDAQ:MNMD),(NASDAQ:ATAI),(NEO:MMED) EQNX::TICKER_END

CMPS : 6.45 (+2.38%)
CYBN.NE : 8.3000 (+1.97%)
ATAI : 4.44 (-0.22%)
MMED.NE : 14.9000 (+9.48%)
SAGE : 8.68 (-0.23%)
MNMD : 12.65 (-2.69%)
CYBN : 5.93 (+0.34%)
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

SAGE : 8.68 (-0.23%)
PHAT : 14.56 (-2.28%)
Stocks Settle Higher on Possible De-Escalation of Israel-Iran War

The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.94%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.75%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.42%. June E-mini S&P futures...

SRPT : 22.31 (+2.06%)
ADI : 277.31 (-0.65%)
LVS : 66.05 (-1.54%)
SLB : 38.36 (+0.31%)
WYNN : 123.98 (-2.48%)
SAGE : 8.68 (-0.23%)
ELV : 330.61 (+0.06%)
OXY : 41.67 (+0.75%)
FANG : 158.81 (+0.82%)
AMD : 222.36 (+0.57%)
SPY : 684.94 (+0.19%)
NOC : 553.80 (+0.04%)
Stocks Rally as Iran Signals it Wants an End to Hostilities

The S&P 500 Index ($SPX ) (SPY ) is up +1.15%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.49%. June E-mini S&P futures (ESM25 ) are...

SRPT : 22.31 (+2.06%)
LVS : 66.05 (-1.54%)
SLB : 38.36 (+0.31%)
WYNN : 123.98 (-2.48%)
SAGE : 8.68 (-0.23%)
ELV : 330.61 (+0.06%)
OXY : 41.67 (+0.75%)
FANG : 158.81 (+0.82%)
AMD : 222.36 (+0.57%)
SPY : 684.94 (+0.19%)
UHS : 225.20 (-0.41%)
HCA : 488.30 (+0.65%)
Stocks Rebound on Hopes Israel-Iran Conflict Will be Contained

The S&P 500 Index ($SPX ) (SPY ) is up +0.79%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.73%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.98%. June E-mini S&P futures (ESM25 ) are...

AMAT : 267.50 (-0.25%)
ROKU : 104.49 (+2.74%)
AVGO : 405.42 (+1.08%)
KALV : 16.67 (-1.13%)
SRPT : 22.31 (+2.06%)
LVS : 66.05 (-1.54%)
WYNN : 123.98 (-2.48%)
SAGE : 8.68 (-0.23%)
$IUXX : 25,673.58 (+0.18%)
UNH : 323.78 (+0.05%)
ELV : 330.61 (+0.06%)
ZNH26 : 112-075 (-0.01%)

Business Summary

SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product...

See More

Key Turning Points

3rd Resistance Point 8.78
2nd Resistance Point 8.76
1st Resistance Point 8.72
Last Price 8.68
1st Support Level 8.66
2nd Support Level 8.64
3rd Support Level 8.60

See More

52-Week High 11.44
Fibonacci 61.8% 8.83
Last Price 8.68
Fibonacci 50% 8.03
Fibonacci 38.2% 7.22
52-Week Low 4.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar